U.S. Patent and Trademark Office, U.S. DEPARTMENT Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of contains a valid OMI

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10563226	
Filing Date		2006-01-03	
First Named Inventor	Tada	hiro OHMI	
Art Unit			
Examiner Name			
Attorney Docket Numb	er	SUGI0161	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines when Relevant Passages or Relev Figures Appear					
	1										
If you wis	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	70
	1	2001-201414	JP		A	2001-07-27	SMC CORP				Z
	2	6-201417	JP		A	1994-07-19	GIJUTSU KAIHAT SOGO; KABUSHI KAISHA; EBATA	KI			V
	3	61-202120	JP		A	1986-09-06	HITACHI LTD.				

# Application Number 10583226 Filing Date 2006-01-03 Filing Date 2006-01-03 Filing Date 1058329 Filing Date

	4	59-52450	JP	В	1984-12-19	HITACHI LTD.			
	5	53-88757	JP	A	1978-08-04	HITACHI LTD.		V	
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add		
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Cite Initials* Cite Cook, a serial special country of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/off country where publisher.							Тŝ	
	1								
If you wis	h to a	dd additional non-pater	t literature docu	ment ci	tation informati	on please click the Add	button Add		
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Tace Kint Code of USPTO Petert Documents at Invest/ISPTO.000/c or MPEP 901.04. Tester of tice that issued the document, by the Involved roods (WIPO Standard ST.3). "For impresse patient comment, the involved on the year of the register or impressed the seath undervied the patient code (WIPO Standard ST.3). "For impressed the seath undervied the patient code (WIPO Standard ST.3). "For impression is standard standard ST.3 ("For impression standard ST.3 ("For impr

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10563226
Filing Date		2006-01-03
First Named Inventor	Tadal	hiro OHMI
Art Unit		
Examiner Name		
Attorney Docket Numb	er	SUGI0161

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	--------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(a)(1).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no terior information disclosure statement was known to any individual designated in 37 CFR 1/50(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/37(0.0).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-04-20
Name/Print	Joerg-Uwe Szipi	Registration Number	31799

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Gad 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1436, Alexandria, V.S. 2213.1-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2213.1-450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.